Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study

Neuropsychopharmacology

Volumn 37, Issue 6, 2012, Pages 1526-1533

  Ibrahim, Lobna ^a   Diazgranados, Nancy ^a,b   Franco Chaves, Jose ^a   Brutsche, Nancy ^a   Henter, Ioline D ^a   Kronstein, Phillip ^a,c   Moaddel, Ruin ^d   Wainer, Irving ^d   Luckenbaugh, David A ^a   Manji, Husseini K ^e   Zarate Jr , Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

antidepressant; depression; glutamate; ketamine; NMDA; riluzole

Indexed keywords

KETAMINE; PLACEBO; RILUZOLE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; PATIENT COMPLIANCE; PERCEPTION DISORDER; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL IDEATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DEPRESSION; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RILUZOLE; TIME FACTORS; YOUNG ADULT;

EID: 84859777474     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.338     Document Type: Article

References (33)

1. Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS et al 2010 Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67 139-145.
2. Aitken RC (1969). Measurement of feelings using visual analogue scales. Proc R Soc Med 62: 989-993.
3. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL et al (2008). Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15: 501-511.
4. Beck AT, Beamesderfer A (1974). Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 7: 151-169.
5. Beck AT, Kovacs M, Weissman A (1979). Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol 47: 343-352. (Pubitemid 9157284)
6. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354. (Pubitemid 30109248)
7. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125-136. (Pubitemid 28097797)
8. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S et al (2010a). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
9. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA et al (2010b). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71: 1605-1611.
10. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z et al (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32: 793-802. (Pubitemid 46426179)
11. First MB, Spitzer RL, Gibbon M, Williams AR (2001). Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York State Psychiatric Institute, Biometrics Research: New York.
12. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO (2004). Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 24: 123-128. (Pubitemid 38233735)
13. Gourley SL, Espitia JW, Sanacora G, Taylor JR (2012). Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology 219: 805-814.
14. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
15. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
16. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
17. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA (2012). Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 100: 678-687.
18. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate Jr CA (2008). Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69: 946-958. (Pubitemid 351944948)
19. Maeng S, Zarate Jr CA (2007). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 9: 467-474. (Pubitemid 350284937)
20. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352. (Pubitemid 351146651)
21. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010). Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13: 71-82.
22. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389. (Pubitemid 9136500)
23. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812.
24. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101,606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol 28: 631-637.
25. Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2011). Evaluation of sigma receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol e-pub ahead of print 10 September 2011.
26. Sackeim HA (2001). The definition and meaning of treatmentresistant depression. J Clin Psychiatry 62(Suppl 16): 10-17.
27. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V et al (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61: 822-825. (Pubitemid 46330247)
28. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7: 426-437. (Pubitemid 351619114)
29. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B et al (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191: 122-127.
30. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435. (Pubitemid 9006756)
31. Zarate Jr C, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G (2010). Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18: 293-303.
32. Zarate Jr CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161: 171-174. (Pubitemid 38419327)
33. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006). A randomized trial of an Nmethyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864. (Pubitemid 44188478)